19th Annual Meeting of the European Council for Cardiovascular Research (ECCR)

Friday 23rd – Sunday 25th October 2015
Poiano – Lake Garda, ITALY

www.eccr.org

FINAL PROGRAMME
Welcome............................................................................................................................ 3

General Information.................................................................................................................... 4

Oral Programme
Friday 23rd October 2014........................................................................................................... 5-6
Saturday 24th October 2014........................................................................................................ 7-8
Sunday 25th October 2014.......................................................................................................... 9

Poster Programme
P1 Arterial Stiffness and Atherosclerosis..................................................................................10
P2 Blood Pressure.......................................................................................................................10
P3 Cardiovascular Disease.........................................................................................................11
P4 Endocrine Hypertension.......................................................................................................11-12
P5 Endothelium........................................................................................................................12
P6 Metabolic Aspects of Cardiovascular Disease.....................................................................12
P7 Oxidative Stress....................................................................................................................12-13
P8 Pharmacology.....................................................................................................................13
P9 Renal Biology and Disease....................................................................................................13
P10 Vascular Biology................................................................................................................13-14

Sponsors....................................................................................................................................15-16

ECCR
Executive Committee

President: Gian Paolo Rossi
President-Elect: Jo De Mey
F. Jaisser
M. Baumann
R. Touyz
E. Van Bavel
K. Reesink
C. Peiró
C. Aalkjaer
O. Pechanova
D. Rizzoni

ECCR
Advisory Board

G. Bianchi
P.S. Sever
P. Corvol
H.A.J. Struijker Boudier
X. Jeunemaitre
T. Unger
M. Paul
M.J. Mulvany
A. Hughes
U. Steckelings

Charity
Charity The ECCR is a Registered Charity in the U.K.
Charity No: 1078280

Secretariat
Hampton Medical,
4 – 6 Crane Mead, Ware, Hertfordshire, SG12 9PW, UK
Tel: + 44 (0) 1920 88 5164
Fax: + 44 (0) 1920 88 5102
Email: eccr@hamptonmedical.com
Web: www.eccr.org and www.hamptonmedical.com
Dear Colleagues,

On behalf of the Executive Committee, I would like to welcome you to The 19th Annual Meeting of the European Council for Cardiovascular Research (ECCR) and to Poiano (Garda) on the beautiful Lake Garda, Italy.

This year we were fortunate enough to be able to assemble a very exciting program spanning from the emerging concept of Mitochondrial Medicine to key clinical issues as the treatment for drug Resistant Hypertension. Moreover, for the first time we will start earlier on Friday morning with "How to Sessions", which are devoted to PhD students and post-doc, with the hope to facilitate their future research. The Faculty comprises world-class speakers and opinion leaders, including several past Presidents of the ECCR, the European Society of Hypertension and the current President of International Society Hypertension.

We would like to take the opportunity to thank all ECCR members and their Colleagues who have submitted abstracts for inclusion in the programme. We are also grateful to those members who have assisted the Executive Committee in its difficult task of reviewing the abstracts and compiling the oral and poster programme.

As with the tradition of ECCR, particular emphasis is placed on the participation of young clinicians and scientists to facilitate discussion with key opinion leaders and to promote rapid dissemination of best clinical practice. This is reflected by ECCR’s collaboration with the European educational network COST ADMIRE, which has been actively involved in the 2015 meeting.

As will be seen from the programme, there will be ample time for discussion and exchanges of opinion in a warm and friendly environment. In addition, there are discussion periods for poster groups, and all posters will be displayed for the entire duration of the conference.

The Executive Committee also wishes to thank our sponsors and supporters for their invaluable support of the Council and the Annual Scientific Meeting.

We are looking forward to seeing you in Poiano.

With my very best wishes

Prof. Gian Paolo Rossi

ECCR President
**SECRETARIAT AND REGISTRATION DESK**
The conference organisers will be pleased to assist you with any queries. The desk will be open as follows:

- **Friday 23rd October**: 08.00 – 19.00hrs
- **Saturday 24th October**: 08.00 – 17.00hrs
- **Sunday 25th October**: 08.00 – 14.00hrs

**Telephone Calls for the Conference Desk**
Poiano Resort, Garda, Italy
Tel: +39 (0) 45 7200994 int.8853

**Poster Presentations**
Posters will be displayed for the duration of the meeting.

- **Chaired Poster Discussion**: Sunday 25th October: 10.00 – 12.00hrs
- **Presentation of prizes**: Sunday 25th October: 12:00 – 12:30hrs

---

The Executive Committee wishes to thank the following organisations for their support of the ECCR:

- Vicore Pharma
- Attoquant
- DMT
- MDE
- Trust Medical
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Presenter(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>10.00-13.00</td>
<td>Research Workshop: Update on technology for Cardiovascular Research</td>
<td>Welcome by Gian Paolo Rossi</td>
</tr>
<tr>
<td>10.00-10.30</td>
<td><strong>Course in Molecular Medicine</strong></td>
<td><em>Frederic Jaisser, France</em> How to choose and make knockout mice</td>
</tr>
<tr>
<td>10.30-11.00</td>
<td><strong>Course in Vascular Research</strong></td>
<td><em>Giorgio Valle, Italy</em> How to perform exome capture</td>
</tr>
<tr>
<td>11.00-11.30</td>
<td><strong>Course in Vascular Research</strong></td>
<td><em>Patrick Lacolley, France</em> How to investigate the large arteries</td>
</tr>
<tr>
<td>11.30-12.00</td>
<td><strong>Course in Hypertension Research</strong></td>
<td><em>Damiano Rizzoni, Italy</em> How to investigate the small arteries</td>
</tr>
<tr>
<td>12.00-12.30</td>
<td><strong>Course in Hypertension Research</strong></td>
<td><em>Ben Janssen, Netherlands</em> How to measure BP and CV indexes with telemetry</td>
</tr>
<tr>
<td>12.30-13.00</td>
<td><strong>Course in Hypertension Research</strong></td>
<td><em>Sverre Kjeldsen, Norway</em> How to design, perform and interpret randomized clinical trials</td>
</tr>
<tr>
<td>13.00-14.00</td>
<td><strong>Lunch and review of posters</strong></td>
<td></td>
</tr>
<tr>
<td>14.00-15.00</td>
<td><strong>Keynote Lecture</strong></td>
<td><em>Thomas Unger, Maastricht</em> The protective arm of RAS Chairs: Jo De Mey and Olga Pechanova</td>
</tr>
<tr>
<td>15.00-16.30</td>
<td><strong>Session 1: Oxidative Stress and Cardiovascular disease: does it matter?</strong></td>
<td>Chairs: Ulrike Stekelings and Concepción Péiró</td>
</tr>
<tr>
<td>15.00-15.30</td>
<td><strong>Rhian Touyz, UK</strong></td>
<td><em>Assessing oxidative stress from bed to bedside: challenges and opportunities</em></td>
</tr>
<tr>
<td>15.30-15.40</td>
<td>1.1</td>
<td><em>Concepción Péiró, Autonomous University of Madrid, Madrid</em> The adipokine soluble dipeptidyl peptidase-4 impairs microvascular reactivity through proteinase-activated receptor-2 and thromboxane A2</td>
</tr>
<tr>
<td>15.40-15.45</td>
<td><strong>Discussion</strong></td>
<td></td>
</tr>
<tr>
<td>15.45-15.55</td>
<td>1.2</td>
<td><em>Patrick Lacolley, Paris Cardiovascular Research Center, Vandoeuvre-lès-Nancy</em> Conditional inactivation of the integrin av subunit in vascular smooth muscle cells regulates fibrosis in vessels</td>
</tr>
<tr>
<td>15.55-16.00</td>
<td><strong>Discussion</strong></td>
<td></td>
</tr>
</tbody>
</table>
16.00 – 16.10  1.3  **Christian Aalkjaer, Aarhus University, Aarhus**  
The role of cholinergic receptors for nerve mediated responses of rat mesenteric resistance arteries in vivo

16.10 – 16.15  Discussion

16.15 – 16.25  1.4  **Maria Philippova, Basel University Hospital, Basel**  
Protective activity of human plasma against oxidized phospholipids as a novel biomarker in cardiovascular disease

16.25 – 16.30  Discussion

16.30 – 17.00  **Coffee break**

17.00 – 18.00  **Keynote Lecture**  
Peter de Leeuw, The Netherlands  
Baroreceptor activation therapy  
Chairs: Gian Paolo Rossi and Rhian Touyz

19.30  Dinner at Poiano
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 09.00 – 10.30| **Session 2: Obesity, adipocyte-derived vasoactive factors and hypertension: does VAT contribute to blood pressure?**
|              | Chairs: Koen Reesink and Thomas Unger                                    |
| 09.00 – 09.30| **Keynote Lecture**                                                       |
|              | *Michel Azizi, France*                                                   |
|              | *Current status of non-pharmacological approaches to treatment of resistant hypertension* |
|              | Chairs: Koen Reesink and Thomas Unger                                    |
| 09.30- 10.30 | **Tony Heagerty, UK**                                                    |
|              | *Pros and Cons*                                                          |
| 10.30 – 11.00| **Coffee break**                                                         |
| 11.00 – 12.00| **Session 3: Vascular Biology**                                          |
|              | Chairs: Ludovit Paulis and Frederic Jaisser                              |
| 11.00 – 11.10| **3.1 Koen Reesink, Maastricht University, Maastricht**                   |
|              | *Type 2 diabetes is associated with greater carotid stiffness and greater pressure-dependency of carotid stiffness -The Maastricht Study* |
| 11.10 – 11.15| **Discussion**                                                           |
| 11.15 – 11.25| **3.2 Ana Briones, Autonomous University of Madrid, Madrid**             |
|              | *G protein-coupled receptor kinase 2 mediates aldosterone production from adipocytes in hypertension through reactive oxygen species and COX-2/mPGES-1 derived prostanoids* |
| 11.25 – 11.30| **Discussion**                                                           |
| 11.30 – 11.40| **3.3 Carmine Savoia, University of Rome, Rome**                         |
|              | *Early functional and structural alterations of resistance arteries in mice treated with the inhibitor of the vascular endothelial growth factor receptor vatalanib* |
| 11.40 – 11.45| **Discussion**                                                           |
| 11.45 – 11.55| **3.4 Emma Batchen, University of Edinburgh, Edinburgh**                 |
|              | *Fetal heart function at E15.5 is influenced by maternal glucocorticoid receptor (Nr3c1) haploinsufficiency but is unaffected by early antenatal glucocorticoid treatment* |
| 11.55 – 12.00| **Discussion**                                                           |
| 12.00 – 13.15| **Session 4: Immunity and Vascular Disease**                            |
|              | Chairs: Jo De Mey and Olga Pechanova                                      |
| 12.00 - 12.30| **Anthony Vinh, Australia**                                              |
|              | *Immune mechanisms in hypertension*                                      |
| 12.30 – 12.40| **Natalia Alenina, MDC, Berlin**                                         |
|              | *ACE2 is required for the exercise-induced effect on adult neurogenesis*  |
12.40 – 12.45  
Discussion

12.45 – 12.55  4.2 Mirco Menegolo, University of Padova, Padova
Urotensin II exerts a pressor effect via stimulation of renin and aldosterone secretion

12.55 – 13.00  
Discussion

13.00 – 13.10  4.3 Martin Stenelo, University of Southern Denmark, Denmark
The angiotensin AT2 receptor agonist compound 21 inhibits platelet aggregation through thromboxane receptor antagonism

13.10 – 13.15  
Discussion

13.15 – 15.15  Lunch and review of posters

15.15 – 17.30  Session 5: Hypertension and the organ damage
Chairs: Christian Aalkjaer and Koen Reesink

15.15 – 15.25  5.1 Waed Abdel Khalek, Paris Cardiovascular Research Center, Paris
Gordon syndrome-causing cullin 3 mutant is more neddylated and results in a less efficient e3 ubiquitin ligase complex despite increased affinity for substrates

15.25 – 15.30  Discussion

15.30 – 15.40  5.2 J. Rafael Sádaba, Navarrabiomed Miguel Servet Foundation, Pamplona
A role for Galectin-3 in calcific aortic valve stenosis

15.40 – 15.45  Discussion

15.45 – 15.55  5.3 Maarten Heusinkveld, Maastricht University, Maastricht
Towards in vivo biaxial characterisation of carotid artery mechanics

15.55 – 16.00  Discussion

16.00 – 16.30  
Xavier Jeunemaitre, France
Dissecting the molecular mechanisms of hyperkaliemic hypertension

16.30 – 17.30  Keynote Lecture
Sarino Rizzuto, Italy
Mitochondrial medicine: how to study mitochondrial functions in human cardiovascular diseases
Chairs: Gian Paolo Rossi and Hans Ibsen

17.30 – 18.30  ECCR Business Meeting

17.30  Time at leisure

19.15  Meet at Poiano reception for transfer to dinner at Tre Camini
Session 6: Update on the Renin Angiotensin System-Aldosterone and the Mineralocorticoid Receptor
In conjunction with The European Co-operation in Science and Technology (COST) network on Aldosterone and the Mineralocorticoid Receptor (COST-ADMIRE)
Chairs: Frederic Jaisser and Olga Pechanova

08.00 – 08.30
Natalia Lopez-Andres, Spain
Molecular mechanisms of aldosterone-induced cardiovascular and renal damage

08.30 – 09.00
Brian Harvey, UK
The protein kinase D family - novel regulators of aldosterone actions on enac

09.00 – 10.00
Young Investigator Competition
Chairs: Michael Bader and Michael Mulvany

09.00 – 09.10
Adam Harvey, University of Glasgow, Glasgow
Role of aldosterone and NADPH oxidases during premature vascular aging in hypertension

09.10 – 09.15
Discussion

09.15 – 09.25
Azra Alajbegovic, Lund University, Sweden
Role of transcription factors MRTFA and GATA6 in phenotypic modulation of vascular smooth muscle cells (VSMCs)

09.25 – 09.30
Discussion

09.30 – 09.40
Hien Tran, Lund University, Sweden
Elevated glucose levels promote contractile and cytoskeletal gene expression in vascular smooth muscle via Rho/protein kinase C and actin polymerization

09.40 – 09.45
Discussion

09.45 – 09.55
Giacomo Rossitto, Padova University, Padova
Effect of acute DA2 dopaminergic receptor blockade on the performance of adrenal vein sampling for subtyping of primary aldosteronism

09.55 – 10.00
Discussion

10:00 – 12:00
Poster Review

12:00 – 12:30
Presentation of prizes

12.30
Adjourn
Poster Group P1 Arterial Stiffness and Atherosclerosis
Chair: Koen Reesink

P1.1 Is Aortic pulse wave velocity a marker of asymptomatic carotid atherosclerosis?
Renáta Marietta Böcskei, Béla Benczúr, Miklós Illyés, Thomas Kahan, Attila Cziráki (Hungary)

Poster Group P2 Blood Pressure
Chair: Koen Reesink

P2.1 Remodelling of the aorta and kidney in L-NAME-induced hypertension in rats: comparison of the protective effect of ivabradine with captopril and melatonin
Fedor Simko, Kristina Repova, Kristina Krajićirovicova, Silvia Aziriova, Ludovit Paulis, Tomas Baka (Slovakia)

P2.2 Cardiac and vascular tissue properties determine the central blood pressure waveform: Consequences for pulse wave analysis
Maarten Heusinkveld, Bart Spronck, Joost Lumens, Tammo Delhaas, Alun Hughes, Koen Reesink (Netherlands)

P2.3 Equivalency Validation of a Novel Freely Moving Animal Based Telemetry System versus a Stationary Cage Bound System for Blood Pressure Recordings
Harm Knot, Gary Miller (Germany)

P2.4 Reduced sleep efficiency and increased sile latency are associated with non-dipping pattern in resistant hypertensive patients
Rosa Maria Bruno, Elisa Di Coscio, Michelangelo Maestri, Di Galante Marco, Tommaso Banfi, Martina Cargioli, Lorenzo Ghiadoni, Enrica Bonanni, Ugo Faraguna, Stefano Taddei (Italy)

P2.5 Calcium sensitization and calcium entry in salt hypertensive Dahl rats
Josef Zicha, Michal Behuliak, Ivana Vaneckova (Czech Republic)

P2.6 Validation of an automated chemiluminescent assay of renin and aldosterone in the work-up of arterial hypertension
Gian Paolo Rossi, Giulio Ceolotto, Giacomo Rossitto, Teresa Maria Seccia, Giuseppe Maiolino, Chiara Berton, Daniela Basso, Mario Plebani (Italy)

P2.7 Expression of Particular Components of Catecholaminergic System in Adrenal Medulla and Sympathetic Ganglia of Spontaneously Hypertensive Rat: Importance of the Selection of Appropriate Reference Genes
Anna Vavrinova, Michal Behuliak, Josef Zicha (Czech Republic)

P2.8 Human sry increases blood pressure and alters renin-angiotensin system gene expression
Antonio Peluso, Fabiana Alves, Franscisco Vieira, Amy Milsted, Jeremy Prokop, Monte Turner, Robson Santos, Almir Martins (Denmark)

P2.9 Effect of inhibition of voltage-dependent calcium channels trafficking by gabapentin on blood pressure and baroreflex sensitivity in spontaneously hypertensive rats: the role of sympathetic nervous system
Michal Behuliak, Michal Bencze, Anna Vavrinova, Ivana Vaneckova, Jaroslav Kunes, Josef Zicha (Czech Republic)
Poster Group P3 Cardiovascular Disease

Chair: Hans Ibsen

P3.1 Pericardial Fluid Adipokine Levels and Cardiovascular Disease Patient Characteristics
Atlanta Elie, Pia Jensen, Aimin Xu, Erfei Song, Maria Hansen, Akhmadjon Irmukhamedov, Lars Rasmussen, Yu Wang, Jo De Mey (Denmark)

P3.2 Prolonged angiotensin ii-induced hypertension impairs short-term memory in adult mice

P3.3 Role of adenosine receptors in hypoxic vasodilatation and cardioprotection
Vibeke Bjerg Pedersen, Ulf Simonsen, Elise Røge Hedegaard (Denmark)

P3.4 Simultaneous occurrence of iga glomerulonephritis, hashimoto thyroiditis and severe coronary lesions in a young patient
Delia Voiculescu, Catalina Andrei, Crina Sinescu (Romania)
This paper was co-financed from the European Social Fund, through the Sectorial Operational Programme Human Resources Development 2007-2013, contract POSDRU/159/1.5/S/155463.

P3.5 Experimental autoimmune myocarditis in rats - Optimization of different immunization protocols
Patrick Schmerler (Germany)

P3.6 Mineralocorticoid Receptor activation induces the expression of Neutrophil Gelatinase-Associated Lipocalin in dendritic cells in vitro and during aldosterone-dependent hypertension
Mathieu Buonafine, Basile Gravez, Frédéric Jaisser, Cristian Amador (France)

Poster Group P4 Endocrine Hypertension

Chair: Damiano Rizzoni

P4.1 Cardiac Remodeling in Patients with Primary and Secondary Aldosteronism
Maurizio Cesari, Paolo Angeli, Silvia Rosi, Sara Mareso, Giacomo Rossitto, Gian Paolo Rossi (Italy)

P4.2 Epicardial fat thickness and primary aldosteronism
Antonio Concistrè, Gianluca Iacobellis, Luigi Petramala, Cristiano Marinelli, Camilla Calvieri, Laura Zinnamosca, Gino Iannucci, Giorgio De Toma, Claudio Letizia (Italy)

P4.3 Subclinical atherosclerosis in patients with cushing’s syndrome: evaluation with carotid intima-media thickness and ankle-brachial index
Cristiano Marinelli, Luigi Petramala, Lorenzo D’Elia, Gino Iannucci, Antonio Concistrè, Laura Zinnamosca, Giuseppe De Vincentis, Antonio Ciardi, Giorgio De Toma, Claudio Letizia (Italy)

P4.4 Enhanced soluble serum cd40l and serum p selectin levels in primary aldosteronism due to aldosterone producing adenoma (APA) and adrenal hyperplasia (IHA)
Luigi Petramala, Roberto Carnevale, Cristiano Marinelli, Laura Zinnamosca, Antonio Concistrè, Gino Iannucci, Pasquale Pignatelli, Antonio Ciardi, Francesco Violi, Giorgio De Toma, Claudio Letizia (Italy)

P4.5 Mutations in the promoter region of the Twik-Related Acid-Sensitive K+ Channel 2 (TASK-2) gene in Aldosterone Producing Adenoma
Livia Lenzini, Maniselvan Kuppusamy, Abril Gonzales-Campos, Alberto Scanferla, Gian Paolo Rossi (Italy)
P4.6 Unilateral adrenalectomy for lateralized primary aldosteronism improves the mental health and the depression score at one month
Marilisa Citton, Maurizio Iacobone, Giovanni Viel, Gian Paolo Rossi (Italy)

P4.7 Angiotensin-(1-7) peptide is involved in aldosterone and cortisol production in human adrenocortical cell line (NCI-H295)
Paul Emmanuel Vanderriele, Brasilina Caroccia, Livia Lenzini, Ambrogio Fassina, Teresa Maria Seccia, Gian Paolo Rossi (Italy)

P4.8 Aldosterone Activates CYP11B2 Gene Via GPER-1 Receptor in The Adrenocortical Cells: A Mechanism Involved in The Pathophysiology of Hyperaldosteronism?
Brasilina Caroccia, Teresa Maria Seccia, Alice Limena, Francesca Gioco, Gian Paolo Rossi (Italy)

P4.9 The Adrenal Vein Sampling International Study – 2: Results in 1572 Primary Aldosteronism Patients
Giacomo Rossitto, Paul Emmanuele Vanderriele, Laurance Amar, Martin Reincke, Gian Paolo Rossi (Italy)

**Poster Group P5 Endothelium**
Chair: Christian Aalkaer

P5.1 Vascular ageing is apparent during an oral glucose challenge in healthy humans
Osama Bin Abdullah, Jakob Raunsø, Atheline Major-Pedersen, Thomas Hermann, Thomas Guterbaum, Christian Torp-Pedersen, Michael Hecht-Olsen, Helena Dominguez (Denmark)

P5.2 AT2-receptor stimulation promotes NO release through eNOS serine 1177 phosphorylation and eNOS tyrosine 657 dephosphorylation
Jesper Bertelsen, Antonio Peluso, Kenneth Andersen, Tenna Mortensen, Robson Santos, Pernille Hansen, Ulrike Steckelings (Denmark)

**Poster Group P6 Metabolic Aspects of Cardiovascular Disease**
Chair: Tony Haegerty

P6.1 Bone-cardiovascular axis: biomarkers of bone metabolism as indicators of cardiovascular diseases and predictors of outcomes in orthogeriatric patients
Alexander Fisher (Australia)

P6.2 A role for galectin-3 in the adipose tissue remodelling associated with obesity

P6.3 WITHDRAWN

P6.4 Maternal obesity "rafting" offspring toward cardiovascular disease: Palmitate exposure in utero causes systolic and vascular dysfunction via modified lipid raft structure
Martina Cebova, Catherine J. Knowles, Marilena L. Preda, Calvin P.H. Vary, Ilka M. Pinz (Slovakia)

**Poster Group P7 Oxidative Stress**
Chair: Damiano Rizzoni

P7.1 Complexity of cellular stress reactions induced in endothelium by oxidized phospholipids
Valery Bochkov (Austria)
P7.2 Effect of Fructose Treatment on Nitric Oxide Production and Oxidant Status in Normotensive and Hypertensive Rats
Radoslava Reháková, Stanislava Vranková, Jana Klimentová, Zuzana Matúsková, Andrej Barta, Martina Čebová, Mária Kovácsová, Olga Pechánová (Slovakia)

Poster Group P8 Pharmacology
Chair: Carmine Savoia
P8.1 An adiponectin mimetic causes full relaxation in pericardial resistance arteries from cardiac and vascular disease patients independent of NO production and hyperpolarization
Katrine Dueholm Nissen, Thomas Leurgans, Akhradjon Irmukhamedov, Jo G.R. De Mey (Denmark)

P8.2 Effects of nanoparticle-loaded aliskiren on structural alterations in the heart and aorta
Olga Pechanova, Martina Cebova, Andrej Barta, Jana Klimentova, Radoslava Rehakova, Zuzana Matuskova, Maria Kovacsova (Slovakia)

P8.3 S-nitrosation treatment decreases the AT2R-mediated vasodilation of middle cerebral arteries in rats.
Ml. Bouressam, C. Perrin-sarrado, S. Fouliquier, T. Unger, I. Lartaud, F. Dupuis (Netherlands)

P8.4 Vasoconstrictor Conditions Determine Effects of Nitric Oxide and Hydrogen Peroxide in Cardiovascular Disease Patients’ Pericardial Resistance Arteries
Thomas M. Leurgans, Maria Bloksgaard, Lars Melholt Rasmussen, Akhradjon Irmukhamedov, Jo G. R. De Mey (Denmark)

Poster Group P9 Renal Biology and Disease
Chair: Ludovit Paulis
P9.1 Administration of cyclosporine A in pregnant rats - the effect on blood pressure and on the glomerular number in their offspring
Natalia Slabiak-Blaz, Marcin Adamczak, Nadezda Gut, Aniela Grajoszek, Jens R. Nyengaard, Eberhard Ritz, Andrzej Wiecek (Poland)

P9.2 Role of Angiotensin Type 2 (AT2) receptor activation in cyclosporine nephropathy
Giovanna Castoldi, Cira di Gioia, Raffaella Carletti, Silvia Maestroni, Francesca Roma, Gianpaolo Zerbini, Andrea Stella (Italy)

Poster Group P10 Vascular Biology
Chair: Ulrike Steckelings
P10.1 Age and structural alterations in subcutaneous small resistance arteries in hypertensive patients
Carolina De Ciuceis, Claudia Rossini, Claudia Agabiti Rosei, Enzo Porteri, Alice Gavazzi, Stefano Caletti, Paola Pileri, Maria Antonietta Coschignano, Enrico Agabiti Rosei, Damiano Rizzoni (Italy)

P10.2 Structural alterations of subcutaneous small resistance arteries in resistant hypertension
Claudia Agabiti Rosei, Carolina De Ciuceis, Claudia Rossini, Maria Lorenza Muiesan, Massimo Salvetti, Enzo Porteri, Alice Gavazzi, Anna Paini, Stefano Caletti, Maria Antonietta Coschignano, Paola Pileri, Enrico Agabiti Rosei, Damiano Rizzoni (Italy)

P10.3 Conditional inactivation of av integrin in vascular smooth muscle cells decreases thrombin generation and
thrombosis in a mouse model
Amel Mohamadi, Zhenlin Li, Huguette Louis, Mustapha Bourhim, Patrick Lacolley, Véronique Regnault (France)

P10.4 The role of miRNA-143/145 for mechanotransduction in vascular smooth muscle
Anirban Bhattachariya, Thomas Boettger, Thomas Braun, Karl Swärd, Per Hellstrand, Sebastian Albinsson, (Sweden)
MDE Heidelberg new brand for pharmacological and physiological measurements.

In 2014 a new brand appeared for those who are looking for devices to carry out professional physiological measurements on research and development in the medical field. The unique filtering and professional mechanical solutions are the guaranties to have less noise and the precise data whether we are talking about an action potential or pressure measurements. The fusion of the pharmacological research and new human diagnostic portfolios allows the company to equip projects with devices from the preclinical phase to the final clinical phases. The company can carry out worldwide services concerning training delivery installation, local support.

Vicore Pharma has designed, synthesised and patented a unique collection of small non-peptide molecules with selective agonistic effects on the AT2 receptor. The prime candidate drug, Compound 21 (C21), has emerged from an extensive medical chemistry program and has shown excellent pharmacokinetic and pharmaceutical properties. It is well suited for both oral and intravenous administration as well as inhalation. Our first clinical indication is Idiopathic Pulmonary Fibrosis for which disease clinical trials are due in 2016.

Danish Myo Technology

DMT is a life science company with more than thirty years of experience in development, manufacturing and sales of hardware and software for ex-vivo studies in physiology, pharmacology and toxicology.

One of the world’s leading manufacturers of Wire, Pressure and Muscle Strip Myographs as well as Tissue Organ Bath Systems, we are dedicated to providing the user with a high-level mechanical, electrical and software engineering expertise. In this role driven by the requirements of our global customer base, we also provide complete and integrated technologies including surgical, electrophysiological, pharmacological and physiological tools used by the research communities and the pharmaceutical industry.

www.dmt.dk
Attoquant Diagnostics is a Vienna-based service provider specializing in the quantification of peptide hormones in complex biological samples based on a proprietary technology platform. This novel technology has a broad field of application as a tool in research and drug development and allows the accurate measurement of a variety of low abundance peptides in plasma and tissue samples. Our focus is currently set on angiotensins being the effector hormones of the renin angiotensin system. We offer the proprietary RAS-Fingerprint™ as a novel multiplex parameter for the detailed biochemical characterization of the renin angiotensin system.